The Neuropathic Pain Market To Surpass Covid-19 Cringe From 2024 Onwards

Posted by Ashish on December 28th, 2020

Reaching the revenues of over US$ 6 Bn at the end of 2019, the global neuropathic pain management market is projected for a healthy CAGR during the forecast period (2019 – 2029). Increasing prevalence of neuropathic pain disorders and growing awareness about pain medication are boosting the demand for pain management drugs.

Pipeline strategies by manufacturers are focused on introducing advanced drugs with minimum side effects to increase market share. For instance, Pfizer sponsored drug Pregabalin, effective in treating neuropathic (nerve) pain resulting from peripheral nerve trauma that is in phase 3 clinical trials. Increasing research and development activities to develop medications for indications such as post-herpetic neuralgia are creating significant opportunities for manufactures to flourish in the market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4149

Company Profiles

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Sanofi S.A
• GlaxoSmithKline plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd
• Baxter International Inc